Executive Summary
RBI's money market operations across March 31 and April 1, 2026, reveal aggressive net liquidity absorption totaling ₹585,965 Cr on Mar31 (overall ₹309,220 Cr) and ₹445,782 Cr on Apr1 (overall ₹184,555 Cr absorption), driven by heavy SDF usage (₹589,115 Cr on Mar31), signaling tight liquidity management amid stable repo rates of 5.26-5.34%; however, bank reserves flipped from a ₹14,850 Cr shortfall (760,412 Cr vs 775,262 Cr CRR) on Mar31 to a ₹122,457 Cr surplus (₹898,889 Cr vs ₹776,432 Cr) on Apr1, indicating improving system liquidity. Corporate filings show positive expansion at Apollo Hospitals (new Dwarka hospital via 55-year lease, ₹33.3 Cr annual fee from year 5) contrasting neutral RBI compliance updates (counterfeit notes directive) and routine disclosures (Wipro Q4 board meeting Apr15-16, ICICI SAST intent). No YoY/QoQ financial trends or insider volumes detailed, but stable outstanding repo volumes (e.g., ₹50,001 Cr at 5.34%) suggest policy continuity without rate changes. Overarching theme: RBI balancing GoI surplus (₹84,582 Cr as of Mar30) with absorption, bullish for bank margins but cautious for rate-sensitive borrowers. Portfolio implication: Favor financials (surplus reserves) over growth sectors amid potential tightening; watch Wipro earnings for IT sector read-through on macro.
Tracking the trend? Catch up on the prior India Monetary Policy RBI MPC Decisions digest from March 26, 2026.
Investment Signals(11)
- Apollo Hospitals↓(BULLISH)▲
Board approved phased multi-specialty hospital on 9.33-acre DDA lease (55 years, ₹33.3 Cr annual fee from year 5 via SPV), domestic non-RPT, no negative performance; positive sentiment vs neutral peers
- RBI (Apr1 Ops)▲
Banks shifted to ₹122,457 Cr surplus reserves (₹898,889 Cr vs ₹776,432 Cr CRR req for Apr15 fortnight) from Mar31 shortfall, stable repo outstanding (₹50k Cr@5.34%, ₹103k Cr@5.26%) [BULLISH for banks]
SAST Reg 29(2) disclosure for potential acquisition/disposal crossing thresholds, standard compliance with low risk, no volume impact yet; signals activity in large cap bank [BULLISH potential stake build]
- RBI (Mar31 Ops)▲
MSF injection ₹3,150 Cr@5.50% offset by SDF absorption ₹589,115 Cr@5.00%, net ₹586k Cr absorb but stable rates (5.26-5.34%) vs prior ops [BULLISH policy stability]
- Wipro↓(NEUTRAL-BULLISH)▲
Trading window closed Mar16-Apr18 for Q4/YE Mar26 results board approval Apr15-16 (IndAS/IFRS), routine per Reg29(1); neutral but pre-earnings momentum setup
- RBI Counterfeit Directive▲
Consolidated guidelines mandate FNV cells, monthly FIRs/NCRB reporting, machine processing for ₹100+ notes; enhances vigilance without new costs flagged [BULLISH bank compliance edge]
- RBI Overall▲
Repo outstanding stable QoD (₹50k@5.34, ₹34k+65k+103k@5.26 across days), zero volumes in overnight/term segments; continuity supports NIMs [BULLISH financials]
License agreement execution within 1 year, no promoter/DDA links, phased rollout; capacity expansion outlier vs neutral RBI filings [BULLISH growth]
- ICICI Bank↓(BULLISH)▲
SAST filing Apr2 amid RBI surplus shift, potential conviction buy in banks with improving reserves
- RBI Apr1▲
Net daily absorption ₹446k Cr but overall milder ₹185k Cr vs Mar31 ₹309k Cr, GoI surplus integration [BULLISH liquidity normalization]
Q4 results catalyst Apr16 approval, trading window closure limits insider sales [BULLISH discipline]
Risk Flags(8)
- RBI (Mar31 Ops)[HIGH RISK]▼
Massive net absorption ₹585,965 Cr daily (overall ₹309,220 Cr), banks shortfall ₹14,850 Cr (760k vs 775k CRR); liquidity stress pre-Apr1
- RBI (Apr1 Ops)[MEDIUM RISK]▼
Daily net absorption ₹445,782 Cr highest in period, overall ₹184,555 Cr drain despite surplus; potential tightening signal
- ICICI Bank / SAST↓[LOW RISK]▼
Intention to acquire/dispose crossing thresholds undisclosed party/volume/value; ambiguity on buy/sell intent
- RBI Counterfeit[MEDIUM RISK]▼
Banks face new FNV cells, half-yearly reports, immediate FIRs for 5+ fakes, machine mandates; compliance burden on branches/ATMs
- Wipro↓[LOW RISK]▼
Trading window closed to Apr18, delays insider signals; results pending Apr15-16 with no guidance preview
- RBI Overall[MEDIUM RISK]▼
Zero volumes in all money market segments (call/triparty/repo/term) for 2 days; illiquidity risk if persists
- RBI Mar31[HIGH RISK]▼
GoI surplus ₹84,582 Cr auctioned, heavy SDF reliance ₹589k Cr; dependency on govt flows
- Apollo Hospitals↓[LOW RISK]▼
Annual fee ₹33.3 Cr escalations from year 5, SPV phasing delays; capex drag if rates rise
Opportunities(8)
- Apollo Hospitals / Expansion↓(OPPORTUNITY)◆
New Dwarka hospital (9.33 acres, 55-yr lease via SPV), execution <1yr; healthcare capacity alpha vs neutral macro
- ICICI Bank / SAST↓(OPPORTUNITY)◆
Threshold-crossing intent amid RBI surplus ₹122k Cr; position for stake build in top bank at stable 5.26% repos
- Banks / RBI Surplus(OPPORTUNITY)◆
Reserve flip to ₹898k Cr surplus (Apr1 vs Mar31 deficit), supports lending/NIM expansion
- Wipro / Earnings↓(OPPORTUNITY)◆
Apr15-16 board for Q4 IndAS/IFRS results, window closure till Apr18; pre-results dip buy
- RBI Stability(OPPORTUNITY)◆
Repo rates unchanged QoD 5.26-5.34% (stable volumes ₹50k+103k+etc Cr), policy continuity for fixed income
- Financials / Liquidity Norm(OPPORTUNITY)◆
RBI absorption peaks but surplus build (₹776k CRR avg); relative outperformance vs corporates
- Apollo / Phased Growth↓(OPPORTUNITY)◆
Multi-specialty hospital no RPT/promoter links, positive sentiment 8/10 vs RBI neutral
- RBI Counterfeit(OPPORTUNITY)◆
Vigilance upgrades (FNV/monthly reports) differentiate compliant banks; long-term risk mitigation
Sector Themes(5)
- RBI Liquidity Absorption◆
2/2 days massive net drains (₹586k Mar31, ₹446k Apr1 Cr daily), overall ₹309k to ₹185k Cr QoD; tight policy aids bank margins but pressures borrowers [Financials +ve, Corporates -ve]
- Bank Reserve Flip◆
From ₹15k Cr shortfall Mar31 to ₹122k Cr surplus Apr1 (760k→899k Cr vs stable ~776k CRR); improving liquidity trend supports NIMs across SCBs [Bullish Financials]
- Stable Repo Outstanding◆
Identical volumes QoD (₹50k@5.34%, ₹34k/65k/103k@5.26% Cr); no rate shift, zero market volumes signal controlled tightening [Neutral Stability]
- Compliance Mandates◆
RBI counterfeit directive adds reporting/FNV/machine reqs (monthly to RBI/FIU/NCRB); operational drag but vigilance edge for banks [Neutral-Mixed Banking]
- Corporate Expansion Outlier◆
Apollo +ve hospital project (8/10 materiality) vs neutral RBI/Wipro/ICICI (6/2/6); healthcare alpha amid macro neutrality [Healthcare +ve]
Watch List(7)
Q4/YE Mar26 results approval Apr15-16, trading window to Apr18; monitor earnings beat/miss, guidance [Apr15-16, 2026]
DDA agreement within 1 year, phased SPV hospital; watch capex, fee escalations from year 5 [Within 1 year from Apr2]
Follow-up on acquisition/disposal details post Apr2 disclosure; volume/party reveal for stake shift [Post-Apr2, 2026]
- RBI Money Market Ops👁
Daily absorption/volumes post-Apr1, reserve vs CRR trends; rate signal if SDF/MSF spikes [Daily, ongoing]
- RBI Counterfeit👁
Bank FNV half-yearly reports (Mar/Sep ends), monthly data by 7th/15th; compliance impacts [Half-yearly by May15/Jun15, 2026]
- Banks / CRR Fortnight👁
Surplus ₹899k Cr vs ₹776k avg to Apr15; watch if holds or reverses [Apr15, 2026]
- RBI Repo Outstanding👁
Monitor ₹50k@5.34%+ others for unwind/changes; policy pivot clue [Ongoing daily]
Filing Analyses(6)
02-04-2026
Wipro Limited has scheduled its Board of Directors meeting for April 15-16, 2026, to consider and approve the condensed audited standalone and consolidated financial results under IndAS, as well as consolidated financial results under IFRS, for the quarter and year ended March 31, 2026, with approval on April 16, 2026. The trading window for dealing in the Company's securities remains closed from March 16, 2026, to April 18, 2026 (both days inclusive). This intimation is pursuant to Regulation 29(1) of SEBI (LODR) Regulations, 2015.
02-04-2026
Apollo Hospitals Enterprise Limited's Board of Directors approved the establishment of a multi-speciality hospital at Dwarka, New Delhi, on a 9.33-acre land parcel leased from the Delhi Development Authority (DDA) for 55 years. The project will be implemented in phases through a Special Purpose Vehicle (SPV), with the license agreement to be executed within one year and an annual license fee of ₹33.3 Cr starting from the fifth year, subject to escalations. No negative developments or performance declines were reported.
- ·Board meeting held on April 2, 2026, from 4:00 p.m. to 5:45 p.m.
- ·Land allotted on license basis; no promoter/promoter group interest in DDA.
- ·Order/contract is domestic and does not fall within related party transactions.
02-04-2026
ICICI Bank Limited (BSE: 532174) filed a disclosure under Regulation 29(2) of SEBI (SAST) Regulations, 2011 on April 02, 2026 via BSE, notifying an intention to acquire or dispose of shares that could cross substantial acquisition thresholds. No specific details on the trading party, transaction type, volume, value, or holding changes are explicitly stated in the filing. This represents standard regulatory compliance with no disclosed quantitative impact.
02-04-2026
RBI's money market operations as on March 31, 2026, showed zero volumes across all overnight (call money, triparty repo, market repo, corporate bond repo) and term segments (notice money, term money, etc.). RBI injected liquidity via MSF totaling ₹3,150 Cr at 5.50% but absorbed significantly more via SDF totaling ₹589,115 Cr at 5.00%, resulting in net absorption of ₹585,965 Cr from today's operations; overall net liquidity was a absorption of ₹309,220 Cr. Scheduled commercial banks' cash balances stood at ₹760,412 Cr against an average daily cash reserve requirement of ₹775,262 Cr, indicating a shortfall.
- ·Government of India surplus cash balance reckoned for auction as on March 30, 2026: ₹84582 Cr
- ·All money market segments reported zero volume and no applicable rates
- ·Outstanding repo operations include ₹50001 Cr at 5.34%, ₹34581 Cr and ₹65322 Cr at 5.26%, ₹12451 Cr at 5.34%, ₹103375 Cr at 5.26%
02-04-2026
RBI's Money Market Operations report for April 01, 2026 shows zero volumes across all overnight and term segments. Today's operations resulted in net liquidity absorption of ₹4,45,782.00 Cr, leading to overall net liquidity injection of -₹1,84,554.86 Cr including outstanding operations; however, Scheduled Commercial Banks maintain surplus cash reserves of ₹8,98,888.52 Cr against an average requirement of ₹7,76,432.00 Cr for the fortnight ending April 15, 2026.
- ·Outstanding repo operations include ₹50,001.00 Cr at 5.34%, ₹34,581.00 Cr at 5.26%, ₹65,322.00 Cr at 5.26%, ₹12,451.00 Cr at 5.34%, and ₹1,03,375.00 Cr at 5.26%.
- ·MSF outstanding: ₹1,100.00 Cr and ₹100.00 Cr at 5.50%; SDF outstanding: ₹17,333.00 Cr and ₹1,589.00 Cr at 5.00%.
01-04-2026
The Reserve Bank of India (RBI) issued the Master Direction on Counterfeit Notes – Detection, Reporting and Monitoring on April 01, 2026, consolidating all prior guidelines for banks on handling counterfeit currency. Banks must impound detected notes, issue receipts to tenderers, report to police via monthly consolidated reports for up to 4 pieces per transaction or immediate FIR for 5 or more, establish Forged Note Vigilance (FNV) Cells at head offices, and equip branches with detection machines. Notes in denominations of ₹100 and above must be machine-processed before recirculation, ATM loading, or remittance to RBI.
- ·FNV Cells must submit half-yearly status reports (March/September ends) to RBI Issue Offices by fortnight end.
- ·Monthly counterfeit detection data reported to RBI Issue Offices by 7th of following month (Nil report if none).
- ·Counterfeit notes data also reported to FIU-IND by 15th of succeeding month and NCRB web portal.
- ·Banks must designate district-wise Nodal Bank Officers for counterfeit reporting.
- ·High Quality Counterfeit Indian Currency handled under UAPA 1967.
Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 6 filings
🇮🇳 More from India
View all →March 26, 2026
India Pre-Market Regulatory Roundup — March 26, 2026
India Pre-Market Regulatory Roundup
March 26, 2026
India Quarterly Results BSE NSE Announcements — March 26, 2026
India Quarterly Results BSE NSE Announcements
March 26, 2026
India Upcoming Corporate Actions BSE NSE — March 26, 2026
India Upcoming Corporate Actions BSE NSE
March 26, 2026
India MCA Insolvency Liquidation Filings — March 26, 2026
India MCA Insolvency Liquidation Filings